- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Coronary imaging trial zeroes in on plaque risk
A large prospective trial found plaque burden and plaques involving small lumen area are as likely as classically defined vulnerable plaques to trigger a myocardial infarction.
A large prospective trial found plaque burden and plaques involving small lumen area are as likely as classically defined vulnerable plaques to trigger a myocardial infarction.
The Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT) trial is the first study of atherosclerosis using multimodality imaging. Principal investigator Dr. Gregg W. Stone and colleagues at New York-Presbyterian Hospital/Columbia University Medical Center studied 700 patients with acute coronary syndromes using angiography, intravascular ultrasound, and virtual histology analysis of IVUS-acquired radiofrequency data.
Most untreated plaques that cause unexpected heart attacks are not mild lesions, as previously thought, but actually have a large plaque burden and a small lumen area, the researchers found. These characteristics were invisible on the coronary angiogram but easily identifiable on IVUS. Findings were released at the 2009 Transcatheter Cardiovascular Therapeutics scientific symposium in San Francisco.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
